Abstract
Objectives Lower limb immobility is a significant risk factor for peripheral vascular diseases, such as venous thromboembolism (VTE). Restless legs syndrome (RLS) is characterized by an irresistible urge to move the lower limbs to alleviate discomfort. The impact of RLS on lower limb vascular diseases is unclear.
Methods This study used a two-sample Mendelian Randomization (MR) approach to assess the effect of RLS on the risk of seven arterial and seven venous diseases. Conducted in three stages, the study used different RLS datasets for discovery (Didriksen et al.) and replication (EU-RLS-GENE consortium) analyses across all the stages to ensure robust conclusions. Univariable MR (UVMR) was applied to analyze the causal relationship between RLS and 14 vascular diseases. Multivariable MR (MVMR) included covariates like BMI, smoking status, alcohol intake, and educational attainment. In the final stage, accelerometer-based physical activity at 12 different times were incorporated in MVMR analysis to determine if RLS influences lower limb vascular diseases by increasing limb activity.
Results RLS was associated with a reduced risk of six venous diseases, including varicose veins, superficial phlebitis, VTE, and pulmonary embolism. These findings remained robust after adjusting for covariates but lost significance after accounting for nighttime physical activity.
Conclusion RLS may lower the risk of venous diseases and pulmonary embolism by increasing nocturnal limb activity. This finding is particularly relevant for pregnant women and individuals with renal impairment, who are at high risk for both RLS and VTE. Further research is needed to validate these conclusions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Natural Science Foundation of China (grant number 82271454) and the Basic Research Program of the Shenzhen Science and Technology Project (grant number JCYJ20220818102206014).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Please refer to Table S1 for all data sources and download links mentioned in this article.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
